Alcobra Announces Second Quarter 2016 Financial Results And Provides Corporate Update
TEL AVIV, Israel, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced financial results for the three and six months ended June 30, 2016, and provided a corporate update.
Second Quarter Ended June 30, 2016 Financial Results:
* Total operating expenses in the second quarter 2016 were $5.9 million, compared to $5.2 million in the second quarter 2015.
* Net operating expenses, excluding non-cash stock based compensation of $0.6 million, in the second quarter 2016 were $5.3 million, compared with $4.8 million in the second quarter 2015.
Second Quarter Ended June 30, 2016 Financial Results:
* Total operating expenses in the second quarter 2016 were $5.9 million, compared to $5.2 million in the second quarter 2015.
* Net operating expenses, excluding non-cash stock based compensation of $0.6 million, in the second quarter 2016 were $5.3 million, compared with $4.8 million in the second quarter 2015.